NCT02180516已完成不适用
Safety and Efficacy of Meloxicam (MOBIC) Compared to Other NSAIDs in Approved Therapeutic Dosages and Routes of Administration in an Observational Cohort Study of Patients With Rheumatoid Arthritis, Osteoarthritis, Lumbago, Scapulohumeral Periarthritis, Neck, Shoulder and Arm Syndrome
适应症
干预措施
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 9,984
- 主要终点
- Incidence for adverse event of gastrointestinal disorder
研究概览
简要总结
Study to assess the safety profile of meloxicam by comparing incidence of gastrointestinal adverse events of meloxicam with that of NSAID in the routine daily therapeutic situation.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients with Indications according to the package insert of the prescribed NSAID
排除标准
- •There is no exclusion criterion, because this Post Marketing Study is an observational study
研究组 & 干预措施
Meloxicam
干预措施: Meloxicam (Drug)
Other NSAIDs
干预措施: Other Non Steroidal Anti-Inflammatory Drugs (NSAIDs) except etodolac (Drug)
结局指标
主要结局
Incidence for adverse event of gastrointestinal disorder
时间窗: up to 6 months
次要结局
- Incidence for adverse events Perforation, Ulcer and Bleeding (PUB) in the upper gastrointestinal tract(up to 6 months)
- Incidence for adverse drug reaction of gastrointestinal disorder(up to 6 months)
- Incidence of adverse events(up to 6 months)
- Incidence of adverse drug reactions(up to 6 months)
- Incidence of serious adverse events(up to 6 months)
研究者
相似试验
已完成
不适用
Observational Study of Meloxicam in Mexican Patients With Rheumatic DiseasesArthritis, RheumatoidNCT02184065Boehringer Ingelheim22,639
已完成
2 期
Efficacy and Safety of Meloxicam vs. Naproxen Sodium in Patients With Acute Non Bacterial Pharyngitis or Pharyngo-tonsillitisPharyngitisNCT02183038Boehringer Ingelheim390
已完成
1 期
Bioequivalence Study of Meloxicam Capsules 15 mg (Mobic® Capsules 15 mg) Versus Meloxicam Tablets 15 mg (Mobic® Tablets 15 mg) in Healthy Adult VolunteersHealthyNCT02183181Boehringer Ingelheim6
已完成
2 期
Efficacy and Safety Study of Meloxicam Versus Mefenamic Acid in Patients With DysmenorrheaDysmenorrheaNCT02183025Boehringer Ingelheim337
已完成
4 期
Study to Assess the Efficacy and Safety of Meloxicam vs. Diclofenac SR in Patients With Osteoarthritis of the KneeOsteoarthritisNCT02183129Boehringer Ingelheim91